EXPANDING THE THERAPEUTIC OPPORTUNITIES IN ADVANCED PROSTATE CANCER

SUNDAY 29 SEPTEMBER 2019
13:00–14:30
Hall 7
Cordoba Auditorium
Fira Gran Via
Barcelona, Spain

OVERALL LEARNING OBJECTIVES
After attending this meeting, participants should be able to:
- Discuss ongoing changes and the subsequent impact on the treatment landscape of advanced prostate cancer
- Review advances in therapeutic strategies for mHSPC
- Explore practical management of treatment options in nmCRPC

PROGRAM

<table>
<thead>
<tr>
<th>TIME</th>
<th>SESSION</th>
<th>FACULTY</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:00-13:15</td>
<td>Refining the treatment landscape of advanced prostate cancer</td>
<td>Noel Clarke and Nicolas Mottet</td>
</tr>
<tr>
<td>13:15-14:00</td>
<td>Optimising therapeutic strategies in mHSPC</td>
<td>Kim Chi and Álvaro Pinto</td>
</tr>
<tr>
<td>14:00-14:20</td>
<td>Practical identification and current management of patients with nmCRPC</td>
<td>Laura-Maria Krabbe</td>
</tr>
<tr>
<td>14:20-14:30</td>
<td>Understanding advances and defining next steps</td>
<td>Eleni Efstathiou</td>
</tr>
</tbody>
</table>

With the support of Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA
Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse, Belgium

Date of preparation: June 2019
CP-99571

ESMO 2019 Industry Satellite Symposium